AbbVie’s Rinvoq (upadacitinib) Receives NICE Recommendation for the Treatment of Active Ulcerative Colitis
Shots:
- The NICE has issued positive final draft guidance recommending Rinvoq (upadacitinib) as an additional treatment option for adults with moderately to severely active UC despite treatment with conventional or biologic therapies
- The recommendation was based on the P-III (U-ACHIEVE) and (U-ACCOMPLISH) studies as induction therapy evaluating upadacitinib (45mg, qd) along with P-III (U-ACHIEVE) as maintenance therapy evaluating upadacitinib (15/30mg, qd)
- In the induction trials, 26% and 33% of participants achieved the 1EPs of clinical remission @8wks. over 5% & 4% in both studies. In the maintenance trial, 42% & 52% achieved the 1EPs of clinical remission @52wks. over 12% who received PBO for both doses
Ref: PRNewswire | Image: CK Life Sciences
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
